微管抑制剂在血管新生性疾病中的作用机制研究进展  

Research progress on the mechanism of microtubule inhibitors in vascular neoplastic diseases

作　　者：方思尹 刘辰 吴晋晖 FANG Siyin;LIU Chen;WU Jinhui(Department of Ophthalmology,the First Affiliated Hospital,Navy Military Medical University,Shanghai 200433;Department of Ophthalmology,the Third Affiliated Hospital,Navy Military Medical University,Shanghai 200438,China)

机构地区：[1]海军军医大学第一附属医院眼科,上海200433 [2]海军军医大学第三附属医院眼科,上海200438

出　　处：《基础医学与临床》2023年第2期327-331,共5页Basic and Clinical Medicine

基　　金：上海市浦江人才计划(17PJD041);海军军医大学未来战争医学防护技术研发专项(19WLMS-03);上海市中医药管理局项目(ZHYY-ZXYJHZX-202024)。

摘　　要：新生血管性疾病累及多系统和多器官,是以血管新生为特征的一大类疾病,其中包含肿瘤、心血管疾病和眼部疾病等。微管抑制剂是一类通过改变微管状态,从而抑制新生血管生成及阻断新生血管的天然或合成类药物,其可能通过影响血管生成相关基因及细胞因子、诱导细胞凋亡及阻滞细胞周期发挥作用。Neovascular diseases involve multiple systems and organs and are a major category of diseases characterized by angiogenesis,including tumors,cardiovascular diseases and eye diseases.Microtubule inhibitors are a class of natural or synthetic drugs which inhibit neovascularization and block neovascularization through changing the state of microtubules.They may induce apoptosis and block cell cycle by affecting angiogenesis related genes and cytokines.

关 键 词：新生血管性疾病 微管抑制剂 微管 作用机制 

分 类 号：R34[医药卫生—基础医学]